Cargando…

Non-invasive endothelial function assessment in patients with neurofibromatosis type 1: a cross-sectional study

BACKGROUND: Neurofibromatosis type 1 (NF1) is a multi-systemic disease caused by neurofibromin deficiency. The reduced life expectancy of patients with NF1 has been attributed to NF1-associated malignant neoplasms. However, an analysis of death certificates in the USA suggests that vascular disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodrigues, Luiza O, Rodrigues, Luiz Oswaldo C, Castro, Luisa Lima, Rezende, Nilton A, Ribeiro, Antonio Luiz P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3606630/
https://www.ncbi.nlm.nih.gov/pubmed/23497412
http://dx.doi.org/10.1186/1471-2261-13-18
_version_ 1782264036376707072
author Rodrigues, Luiza O
Rodrigues, Luiz Oswaldo C
Castro, Luisa Lima
Rezende, Nilton A
Ribeiro, Antonio Luiz P
author_facet Rodrigues, Luiza O
Rodrigues, Luiz Oswaldo C
Castro, Luisa Lima
Rezende, Nilton A
Ribeiro, Antonio Luiz P
author_sort Rodrigues, Luiza O
collection PubMed
description BACKGROUND: Neurofibromatosis type 1 (NF1) is a multi-systemic disease caused by neurofibromin deficiency. The reduced life expectancy of patients with NF1 has been attributed to NF1-associated malignant neoplasms. However, an analysis of death certificates in the USA suggests that vascular disease could be an important cause of early death among these patients. Endothelial dysfunction (ED) is related to vasculopathy and is an early marker of subclinical atherosclerosis. Since neurofibromin has already been demonstrated to affect endothelial cell function, ED may be associated with NF1. The purpose of this study was to assess endothelial function in patients with NF1 using a non-invasive method. METHODS: NF1 patients and healthy control subjects, aged 18 to 35 years, were included. Subjects were excluded if they had any risk factor for vascular disease or any other condition known to affect endothelial function. Endothelial function was assessed using reactive hyperemia-peripheral arterial tone (RH-PAT) technology. ED was defined as a reactive hyperemia index (RHI) lower than 1.35. RESULTS: Four of the 29 (13.8%) NF1 patients and 1 of the 30 (3.3%) healthy volunteers had ED (p = 0.153). RHI medians and interquartile intervals were 1.8 (1.58-2.43) for the NF1 group and 2.02 (1.74 – 2.49) for the control group (p = 0.361). CONCLUSION: The prevalence of ED was similar in NF1 patients and healthy controls.
format Online
Article
Text
id pubmed-3606630
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36066302013-03-24 Non-invasive endothelial function assessment in patients with neurofibromatosis type 1: a cross-sectional study Rodrigues, Luiza O Rodrigues, Luiz Oswaldo C Castro, Luisa Lima Rezende, Nilton A Ribeiro, Antonio Luiz P BMC Cardiovasc Disord Research Article BACKGROUND: Neurofibromatosis type 1 (NF1) is a multi-systemic disease caused by neurofibromin deficiency. The reduced life expectancy of patients with NF1 has been attributed to NF1-associated malignant neoplasms. However, an analysis of death certificates in the USA suggests that vascular disease could be an important cause of early death among these patients. Endothelial dysfunction (ED) is related to vasculopathy and is an early marker of subclinical atherosclerosis. Since neurofibromin has already been demonstrated to affect endothelial cell function, ED may be associated with NF1. The purpose of this study was to assess endothelial function in patients with NF1 using a non-invasive method. METHODS: NF1 patients and healthy control subjects, aged 18 to 35 years, were included. Subjects were excluded if they had any risk factor for vascular disease or any other condition known to affect endothelial function. Endothelial function was assessed using reactive hyperemia-peripheral arterial tone (RH-PAT) technology. ED was defined as a reactive hyperemia index (RHI) lower than 1.35. RESULTS: Four of the 29 (13.8%) NF1 patients and 1 of the 30 (3.3%) healthy volunteers had ED (p = 0.153). RHI medians and interquartile intervals were 1.8 (1.58-2.43) for the NF1 group and 2.02 (1.74 – 2.49) for the control group (p = 0.361). CONCLUSION: The prevalence of ED was similar in NF1 patients and healthy controls. BioMed Central 2013-03-11 /pmc/articles/PMC3606630/ /pubmed/23497412 http://dx.doi.org/10.1186/1471-2261-13-18 Text en Copyright ©2013 Rodrigues et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Rodrigues, Luiza O
Rodrigues, Luiz Oswaldo C
Castro, Luisa Lima
Rezende, Nilton A
Ribeiro, Antonio Luiz P
Non-invasive endothelial function assessment in patients with neurofibromatosis type 1: a cross-sectional study
title Non-invasive endothelial function assessment in patients with neurofibromatosis type 1: a cross-sectional study
title_full Non-invasive endothelial function assessment in patients with neurofibromatosis type 1: a cross-sectional study
title_fullStr Non-invasive endothelial function assessment in patients with neurofibromatosis type 1: a cross-sectional study
title_full_unstemmed Non-invasive endothelial function assessment in patients with neurofibromatosis type 1: a cross-sectional study
title_short Non-invasive endothelial function assessment in patients with neurofibromatosis type 1: a cross-sectional study
title_sort non-invasive endothelial function assessment in patients with neurofibromatosis type 1: a cross-sectional study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3606630/
https://www.ncbi.nlm.nih.gov/pubmed/23497412
http://dx.doi.org/10.1186/1471-2261-13-18
work_keys_str_mv AT rodriguesluizao noninvasiveendothelialfunctionassessmentinpatientswithneurofibromatosistype1acrosssectionalstudy
AT rodriguesluizoswaldoc noninvasiveendothelialfunctionassessmentinpatientswithneurofibromatosistype1acrosssectionalstudy
AT castroluisalima noninvasiveendothelialfunctionassessmentinpatientswithneurofibromatosistype1acrosssectionalstudy
AT rezendeniltona noninvasiveendothelialfunctionassessmentinpatientswithneurofibromatosistype1acrosssectionalstudy
AT ribeiroantonioluizp noninvasiveendothelialfunctionassessmentinpatientswithneurofibromatosistype1acrosssectionalstudy